At a glance
- Originator Critical Outcome Technologies
- Developer Cotinga Pharmaceuticals; Northwestern University; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Thymidylate synthase modulators; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Cancer
- No development reported Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Li-Fraumeni syndrome; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Recurrent) in Canada (PO)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Li-Fraumeni-syndrome in USA (PO)